Re-treatment of Children with Chronic Hepatitis C Who Did Not Respond to Interferon-alpha Treatment
Overview
Authors
Affiliations
Background: Many patients with chronic hepatitis C do not respond to antiviral treatment. In adult patients the re-treatment of these patients has been extensively investigated. Because the response to re-treatment in children is not well defined we evaluated the efficacy and safety of interferon (IFN)-alpha plus ribavirin in patients who have failed to respond to previous treatment.
Patients And Methods: In an open-label, uncontrolled study, 18 chronically infected children were investigated. Fifteen children had been treated with IFN-alpha plus ribavirin and 3 patients with IFN-alpha alone. Fourteen patients were nonresponders; 4 experienced viral breakthrough during treatment and/or relapse after treatment. Patients received IFN-alpha 3 times per week subcutaneously plus ribavirin for 48 weeks. Sixteen patients were infected with hepatitis C virus (HCV) genotype 1, 2 with genotype 4, and 1 with genotype 3 and co-infection with hepatitis B.
Results: Four patients showed early viral response to therapy and became HCV-RNA negative after 12 weeks. Sustained viral response (HCV-RNA negative 6 months after end of treatment) was documented in 2 of them. These 2 patients belonged to the group of 4 children who relapsed or experienced a viral breakthrough during previous treatment. None of the 14 patients with prior nonresponse had sustained viral response.
Conclusions: Re-treatment with IFN-alpha plus ribavirin may be useful in children who relapsed in a previous antiviral treatment but seems not to be useful in nonresponders. These results are in line with studies from adult patients and should be therefore encouraged to provide a second chance for healing in a subgroup of patients.
Naghi S, Abdel-Ghaffar T, El-Karaksy H, Abdel-Aty E, El-Raziky M, Allam A World J Gastroenterol. 2014; 20(16):4681-91.
PMID: 24782620 PMC: 4000504. DOI: 10.3748/wjg.v20.i16.4681.
Current treatment options and response rates in children with chronic hepatitis C.
Wirth S World J Gastroenterol. 2012; 18(2):99-104.
PMID: 22253515 PMC: 3257449. DOI: 10.3748/wjg.v18.i2.99.